Is neoadjuvant hormonal therapy before radical prostatectomy indicated?

Urologia Internationalis

Volumn 72, Issue 4, 2004, Pages 275-280

  Chun, Judy ^a   Pruthi, Ray S ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CYPROTERONE; ESTRAMUSTINE; FLUTAMIDE; GOSERELIN; LEUPRORELIN; TRIPTORELIN;

ADJUVANT THERAPY; BREAST TENDERNESS; CANCER RECURRENCE; CANCER SURGERY; CHEMICAL ANALYSIS; CLINICAL TRIAL; GASTROINTESTINAL SYMPTOM; GYNECOMASTIA; HEALTH CARE COST; HORMONAL THERAPY; HUMAN; MORBIDITY; NIPPLE TENDERNESS; PATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZATION; REVIEW; TREATMENT INDICATION; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROSTATECTOMY; PROSTATIC NEOPLASMS; RANDOMIZED CONTROLLED TRIALS;

EID: 2942615514     PISSN: 00421138     EISSN: None     Source Type: Journal    
DOI: 10.1159/000077677     Document Type: Review

References (17)

1. Larbie F, Cusan L, Gomez J, et al: Neoadjuvant hormonal therapy: The Canadian experience. Urology 1997;49(3A suppl):56.
2. Van Poppel H, De Ridder D, Elgamal A, et al: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: Interim results of a prospective randomized trial. J Urol 1995;154:429.
3. Hugosson J, Abrahamsson P, Ahlgren G, et al: The risk of malignancy in the surgical margin at radical prostatectomy reduced almost threefold in patients given neo-adjuvant hormone treatment. Eur Urol 1996;29:413.
4. Soloway M, Sharifi R, Wajsman Z, et al: Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol 1995;154:424.
5. Epstein J, Carmichael M, Pizov G, et al: Influence of capsular penetration on progression following radical prostatectomy: A study of 196 cases with long-term followup. J Urol 1993;150:135.
6. Kupelian P, Katcher K, Levin H, et al: Correlation of clinical and pathologic factors with rising prostate-specific antigen profiles after radical prostatectomy alone for clinically localized prostate cancer. Urology 1996;48:249.
7. Scott W, Boyd H: Combined hormone control therapy and radical prostatectomy in the treatment of selected cases of advanced carcinoma of the prostate: A retrospective study based upon 25 years of experience. J Urol 1969;101:86.
8. Abbas F, Scardino P: Why neoadjuvant androgen deprivation prior to radical prostatectomy is unnecessary. Urol Clin North Am 1996;23:587.
9. Labrie F, Dupont A, Cusan L, et al: Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: The first controlled and randomized trial. Clin Invest Med 1993;16:499.
10. Soloway M, Sharifi R, Wajsman Z, et al: Radical prostatectomy alone vs. radical prostatectomy preceded by androgen blockade in cT2b prostate cancer - 24-month results. J Urol 1997;157:160.
11. Goldenberg S, Klotz L, Srigley J, et al: Randomized, prospective, controlled study comparing radical prostatectomy alone and neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. J Urol 1996;156:873.
12. Goldenberg S, Klotz L, Jewett M: A randomized trial of neoadjuvant androgen withdrawal therapy prior to radical prostatectomy: 24-month post-treatment PSA results. J Urol 1997;157:92.
13. Witjes W, Schulman C, Debruyne F: Preliminary results of a prospective randomized study comparing radical prostatectomy versus radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3N0M0 prostatic carcinoma. Urology 1997;49(3A suppl):65.
14. Dalkin B, Ahmann F, Nagle R, et al: Randomized study of neoadjuvant testicular androgen ablation therapy before radical prostatectomy in men with clinically localized prostate cancer. J Urol 1996;155:1357.
15. Fair W, Cookson M, Stroumbakis N, et al: The indications, rationale, and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 1997;49(3A suppl):46.
16. Gleave M, Goldenberg S, Jones E, et al: Biochemical and pathological effects of 8 months of neoadjuvant androgen withdrawal therapy before radical prostatectomy in patients with clinically confined prostate cancer. J Urol 1996;155:213.
17. Oefelein M, Cornum R: Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: The case for monitoring serum testosterone and a treatment decision algorithm. J Urol 2000;164:726.